Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 9/20 | 0.62 |
| ▸ | CD74 | P04233 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20725152 | 0.87 | TP53 (0.55) | MIFCD74POLBMEN1KMT2A | |
| SCHEMBL31667438 | 0.86 | MIF (0.71) | MIFCD74POLBMEN1KMT2A | |
| SCHEMBL31667732 | 0.85 | POLB (0.54) | MIFCD74POLBMEN1KMT2A | |
| SCHEMBL34475640 | 0.82 | POLB (0.52) | MIFCD74POLBMEN1KMT2A | |
| SCHEMBL2757855 | 0.82 | MIF (0.70) | MIFCD74POLBNPC1ALDH1A1 | |
| SCHEMBL20725151 | 0.78 | MIF (0.76) | MIFCD74POLBMEN1KMT2A | |
| SCHEMBL18805693 | 0.78 | MIF (0.82) | MIFCD74ALDH1A1MAPT | |
| SCHEMBL18805695 | 0.77 | IDO1 (0.72) | MIFCD74POLBKMT2AALDH1A1 | |
| SCHEMBL32674495 | 0.77 | MIF (0.59) | MIFCD74POLBMEN1KMT2A | |
| SCHEMBL3270711 | 0.77 | MIF (1.00) | MIFCD74POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643922-B2 | MIF modulators | YALE UNIVERSITY (US) | 2017-05-09 | — | — | US | claimed |
| US-20230404980-A1 | METHODS OF TREATING SPONDYLOARTHRITIS OR SYMPTOMS THEREOF | UNIVERSITY HEALTH NETWORK (CA) | 2023-12-21 | — | — | US | disclosed |
| EP-4237002-A1 | METHODS OF TREATING SPONDYLOARTHRITIS OR SYMPTOMS THEREOF | University Health Network (CA) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022087719-A1 | METHODS OF TREATING SPONDYLOARTHRITIS OR SYMPTOMS THEREOF | UNIVERSITY HEALTH NETWORK (CA) | 2022-05-05 | — | — | WO | disclosed |
| US-10202343-B2 | MIF modulators | YALE UNIVERSITY (US) | 2019-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202343-B2 | MIF modulators | MIF, HMGB2, HMGB3 | MIF 1/4885CD74 15/4885POLB 3527/4885 |
| US-20230404980-A1 | METHODS OF TREATING SPONDYLOARTHRITIS OR SYMPTOMS THEREOF | MIF, SPAST, MMP12 | MIF 1/4885CD74 34/4885POLB 2828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.